Navigation Links
Aratana Therapeutics Appoints Erick Lucera Vice President of Corporate Development
Date:1/24/2013

KANSAS CITY, Kan. and NEW YORK, Jan. 24, 2013 /PRNewswire/ -- Aratana Therapeutics, a biopharmaceutical company developing innovative medicines for cats and dogs (companion animals), today announced the appointment of Erick Lucera as Vice President of Corporate Development.  Mr. Lucera will leverage his broad experience managing investments in healthcare, as well as his network of industry contacts to facilitate business development and investment initiatives for Aratana.

Steven St. Peter , M.D., President and Chief Executive Officer of Aratana Therapeutics, stated, "Erick is well known in the healthcare industry and we are very excited to add him to our team.  His deep understanding of corporate strategy and proven ability to recognize and invest strategically in strong growth opportunities will be paramount to keeping Aratana on its current trajectory."

Mr. Lucera stated, "Aratana represents one of the most attractive investment models I've seen in my 15 years as a healthcare investor.  I am confident the human health industry is beginning to recognize the strategic importance and remarkable value in developing animal health strategies for their assets.  As part of my commitment to positioning Aratana as the partner of choice for these companies, I look forward to bringing in high-quality assets and delivering significant value through successful execution on our business initiatives."

Erick Lucera
Mr. Lucera has more than 15 years of diverse experience in the healthcare public equity markets.  Prior to joining Aratana, Mr. Lucera spent four years as Vice President and Healthcare Analyst at Eaton Vance Investment Managers.  From 2004 to 2007, Mr. Lucera was a Portfolio Manager at Intrepid Capital, where he successfully constructed and managed a portfolio constructed across biotech, pharmaceutical, device, and service companies.  Prior to that, Mr. Lucera held various leadership positions at Independence Investments, including Head of Healthcare Research.  Mr. Lucera began his career as a staff auditor and accountant at PwC.  He holds a CPH in public health from Harvard University, and M.S.F. in quantitative finance from The Wallace E. Carroll Graduate School of Management of Boston College, an MBA from Indiana University Bloomington and a B.S. in accounting from Lerner College of Business and Economics of University of Delaware.

About Aratana Therapeutics
Aratana Therapeutics is a biopharmaceutical company positioned to deliver high quality new medicines that address significant therapeutic needs for cats and dogs (companion animals).  Aratana licenses and develops proprietary, patent-protected compounds acquired from human pharmaceutical and biotechnology companies and then develops strategies to maximize the value of the programs for the animal health market.  For more information, please visit www.aratanatherapeutics.com.

For Investors & Media:
Joshua Drumm , Ph.D. / Andrew Mielach
Tiberend Strategic Advisors, Inc.
(212) 827-0020  
jdrumm@tiberend.com   
amielach@tiberend.com


'/>"/>
SOURCE Aratana Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aratana to Present at Bank of America Merrill Lynch Animal Health Summit
2. Aratana to Participate in Leerink Swanns November Management Access Days
3. Epigenetics Technology Market (Epigenomics, DNA Methylation, Histone Modifications, RNA Interference, Cancer Therapeutics, Personalized Medicine) (2012 - 2017)
4. Topokine Therapeutics Secures Financing from Schooner Capital to Advance Clinical Development of XAF5 Gel
5. PrimeMail, Prime Therapeutics mail-service pharmacy, receives URAC Reaccreditation
6. Northwest Biotherapeutics, Inc. Announces Full Exercise of Over- Allotment Option
7. Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
8. Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
9. Fred Hutchinson Cancer Research Center Partners With GlaxoSmithKline to Develop Muscular Dystrophy Therapeutics
10. Northwest Biotherapeutics Announces Public Offering of Common Stock and Warrants, and Listing on NASDAQ
11. PTC Therapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Ataluren in Duchenne Muscular Dystrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... KEY FINDINGS ... Patient warming and cooling devices ... surgeries, lowering the risks of neurological disorders post cardiac arrests, ... patient warming systems can be segmented into convective warming system, ... reduce the stay at hospitals thus, lowering the healthcare costs ...
(Date:12/8/2016)... , Dec. 8, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO) ... a 2016 Top Workplaces National Standard. To ... ... Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ... on an employee survey administered by WorkplaceDynamics, LLC, a research firm ...
(Date:12/8/2016)... 8 de dezembro de 2016  A Mederi Therapeutics Inc . anunciou ... tratamento não cirúrgico para a doença do refluxo gastroesofágico (DRGE). Foto ... ... Live Stretta procedure performed and broadcast during the ... Wuhan Union Hospital ...
Breaking Medicine Technology:
(Date:12/9/2016)... , ... December 09, 2016 , ... ... through the Pennsylvania Cable Network (PCN) during the summer of 2016. The program ... Grant provided by the United States Department of Health and Human Services Administration. ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital ... and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation ... a few hospitals and facilities have earned this distinction. This is the second ...
(Date:12/8/2016)... Pennsylvania (PRWEB) , ... December 08, 2016 , ... ... Duck Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which ... , “This was our first franchise-wide Quack Gives Back initiative, ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... a Property owned by an affiliate of Seavest, has won a prestigious national ... Southern Chester County ambulatory care center (ACC) was named “Best New Development, MOBs ...
(Date:12/8/2016)... ... , ... CURE Media Group, the nation’s leading digital and print media enterprise ... Cancer in efforts to combat lung cancer, announced CURE Media Group President Michael J. ... Group is honored to team up with Upstage Lung Cancer in order to make ...
Breaking Medicine News(10 mins):